|
Gene: PLEK2 |
Gene summary for PLEK2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PLEK2 | Gene ID | 26499 |
Gene name | pleckstrin 2 | |
Gene Alias | PLEK2 | |
Cytomap | 14q23.3-q24.1 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q9NYT0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26499 | PLEK2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.80e-10 | 5.86e-01 | -0.0811 |
26499 | PLEK2 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.75e-05 | 3.93e-01 | -0.1088 |
26499 | PLEK2 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.69e-08 | 6.48e-01 | -0.1526 |
26499 | PLEK2 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.53e-02 | 2.42e-01 | -0.1464 |
26499 | PLEK2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.83e-11 | 6.19e-01 | -0.059 |
26499 | PLEK2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.22e-04 | 3.34e-01 | 0.096 |
26499 | PLEK2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.24e-06 | 2.97e-01 | 0.0674 |
26499 | PLEK2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.59e-03 | 4.24e-01 | 0.0588 |
26499 | PLEK2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.28e-15 | 4.63e-01 | 0.294 |
26499 | PLEK2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.71e-04 | 2.83e-01 | 0.3859 |
26499 | PLEK2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.81e-03 | 2.10e-01 | 0.3005 |
26499 | PLEK2 | LZE7T | Human | Esophagus | ESCC | 1.85e-03 | 8.68e-02 | 0.0667 |
26499 | PLEK2 | LZE6T | Human | Esophagus | ESCC | 1.27e-03 | 5.59e-01 | 0.0845 |
26499 | PLEK2 | P2T-E | Human | Esophagus | ESCC | 3.10e-33 | 8.99e-01 | 0.1177 |
26499 | PLEK2 | P4T-E | Human | Esophagus | ESCC | 1.51e-31 | 1.01e+00 | 0.1323 |
26499 | PLEK2 | P5T-E | Human | Esophagus | ESCC | 1.49e-07 | 5.04e-01 | 0.1327 |
26499 | PLEK2 | P8T-E | Human | Esophagus | ESCC | 5.32e-12 | 2.09e-01 | 0.0889 |
26499 | PLEK2 | P10T-E | Human | Esophagus | ESCC | 4.24e-06 | 2.74e-01 | 0.116 |
26499 | PLEK2 | P11T-E | Human | Esophagus | ESCC | 5.86e-11 | 9.94e-01 | 0.1426 |
26499 | PLEK2 | P15T-E | Human | Esophagus | ESCC | 4.79e-13 | 6.73e-01 | 0.1149 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031532 | Colorectum | AD | actin cytoskeleton reorganization | 41/3918 | 107/18723 | 2.81e-05 | 5.28e-04 | 41 |
GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
GO:0120034 | Colorectum | AD | positive regulation of plasma membrane bounded cell projection assembly | 33/3918 | 105/18723 | 7.49e-03 | 4.55e-02 | 33 |
GO:0120032 | Colorectum | AD | regulation of plasma membrane bounded cell projection assembly | 53/3918 | 186/18723 | 8.51e-03 | 4.97e-02 | 53 |
GO:00315321 | Colorectum | SER | actin cytoskeleton reorganization | 30/2897 | 107/18723 | 6.38e-04 | 8.64e-03 | 30 |
GO:00313461 | Colorectum | SER | positive regulation of cell projection organization | 75/2897 | 353/18723 | 2.22e-03 | 2.14e-02 | 75 |
GO:01200321 | Colorectum | SER | regulation of plasma membrane bounded cell projection assembly | 43/2897 | 186/18723 | 3.82e-03 | 3.16e-02 | 43 |
GO:0060491 | Colorectum | SER | regulation of cell projection assembly | 43/2897 | 188/18723 | 4.68e-03 | 3.70e-02 | 43 |
GO:00315322 | Colorectum | MSS | actin cytoskeleton reorganization | 41/3467 | 107/18723 | 1.21e-06 | 4.06e-05 | 41 |
GO:00313462 | Colorectum | MSS | positive regulation of cell projection organization | 96/3467 | 353/18723 | 3.44e-05 | 6.70e-04 | 96 |
GO:01200322 | Colorectum | MSS | regulation of plasma membrane bounded cell projection assembly | 51/3467 | 186/18723 | 1.78e-03 | 1.58e-02 | 51 |
GO:00604911 | Colorectum | MSS | regulation of cell projection assembly | 51/3467 | 188/18723 | 2.28e-03 | 1.87e-02 | 51 |
GO:01200341 | Colorectum | MSS | positive regulation of plasma membrane bounded cell projection assembly | 30/3467 | 105/18723 | 7.74e-03 | 4.84e-02 | 30 |
GO:003153218 | Esophagus | ESCC | actin cytoskeleton reorganization | 72/8552 | 107/18723 | 5.03e-06 | 5.31e-05 | 72 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
GO:003153216 | Oral cavity | OSCC | actin cytoskeleton reorganization | 65/7305 | 107/18723 | 4.25e-06 | 4.93e-05 | 65 |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLEK2 | SNV | Missense_Mutation | c.75G>T | p.Trp25Cys | p.W25C | Q9NYT0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
PLEK2 | SNV | Missense_Mutation | rs146989539 | c.925G>A | p.Val309Ile | p.V309I | Q9NYT0 | protein_coding | tolerated(0.1) | benign(0.317) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLEK2 | SNV | Missense_Mutation | c.509C>T | p.Ser170Phe | p.S170F | Q9NYT0 | protein_coding | tolerated(0.2) | benign(0.085) | TCGA-AZ-5407-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLEK2 | SNV | Missense_Mutation | novel | c.689A>G | p.Lys230Arg | p.K230R | Q9NYT0 | protein_coding | tolerated(0.64) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PLEK2 | SNV | Missense_Mutation | c.917N>T | p.Asp306Val | p.D306V | Q9NYT0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PLEK2 | SNV | Missense_Mutation | novel | c.655G>A | p.Ala219Thr | p.A219T | Q9NYT0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PLEK2 | SNV | Missense_Mutation | novel | c.353G>T | p.Arg118Ile | p.R118I | Q9NYT0 | protein_coding | deleterious(0) | benign(0.012) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLEK2 | SNV | Missense_Mutation | novel | c.1031N>C | p.Glu344Ala | p.E344A | Q9NYT0 | protein_coding | tolerated(0.07) | benign(0.246) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
PLEK2 | SNV | Missense_Mutation | novel | c.977N>A | p.Thr326Asn | p.T326N | Q9NYT0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLEK2 | SNV | Missense_Mutation | rs373046007 | c.301N>A | p.Gly101Arg | p.G101R | Q9NYT0 | protein_coding | tolerated(0.66) | probably_damaging(0.944) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |